Stamicis (Tc-99m Sestamibi Kit): Uses, Dosage & Side Effects

What Is Stamicis and What Is It Used For?

Quick Answer: Stamicis is a kit for the preparation of technetium Tc-99m sestamibi, a gamma-emitting radiotracer used in nuclear medicine imaging. After radiolabeling at a licensed radiopharmacy, it is injected intravenously to produce diagnostic images of the heart, parathyroid glands, or breast tissue, allowing physicians to evaluate blood flow and cellular metabolism non-invasively.

Stamicis belongs to a class of medicines known as diagnostic radiopharmaceuticals and, more specifically, to the group of myocardial perfusion imaging agents. It is classified under ATC code V09GA01 (technetium [99mTc] sestamibi). The active substance in the kit, tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate, is a coordination compound that, when combined with radioactive sodium pertechnetate, forms a lipophilic cationic complex called [99mTc]-sestamibi (also known as MIBI). Sestamibi is taken up by metabolically active cells in proportion to regional blood flow and is retained within mitochondria, where its positive charge causes it to accumulate along the mitochondrial membrane potential gradient.

Stamicis itself does not contain radioactivity. It is supplied as a sterile, lyophilized (freeze-dried) powder in a multi-dose vial. The vial is reconstituted at a hospital or commercial radiopharmacy with freshly eluted sodium pertechnetate [99mTc] solution from a technetium-99m generator. After a brief heating step, the radiolabeling reaction is complete and the resulting injectable solution contains Tc-99m sestamibi, which can be divided into patient doses, quality-controlled, and administered intravenously. Because technetium-99m has a physical half-life of only 6 hours, each batch must be prepared on the day of use, and unused activity decays rapidly.

Technetium [99mTc] sestamibi was first introduced in the 1990s and has since become one of the most widely used diagnostic radiopharmaceuticals in the world. It is listed on the World Health Organization's (WHO) Model List of Essential Medicines and is considered an international gold standard for non-invasive evaluation of myocardial perfusion. The European Medicines Agency (EMA) and national regulatory authorities have authorized multiple sestamibi kit products, of which Stamicis is one, manufactured by Curium Pharma and marketed across Europe and other regions.

Approved Indications

Stamicis is authorized for the following diagnostic indications in adults and, with appropriate dose adjustments, in children:

• Myocardial perfusion imaging (MPI): Assessment of regional myocardial perfusion at rest and during stress (exercise or pharmacologic) for the diagnosis and localization of coronary artery disease (CAD), assessment of disease severity and prognosis, evaluation of myocardial viability, and follow-up after revascularization (percutaneous coronary intervention or coronary artery bypass grafting).
• Myocardial function imaging: Gated single-photon emission computed tomography (SPECT) acquisition with Tc-99m sestamibi enables simultaneous assessment of left ventricular ejection fraction, regional wall motion, and wall thickening, providing both perfusion and function information from a single injection.
• Parathyroid scintigraphy: Localization of hyperfunctioning parathyroid tissue (adenoma or hyperplasia) in patients with primary or secondary hyperparathyroidism, especially before minimally invasive parathyroidectomy. Dual-phase protocols or dual-isotope techniques exploit the differential washout kinetics between thyroid and parathyroid tissue.
• Scintimammography (breast imaging): Evaluation of suspected breast cancer in patients with inconclusive mammography or dense breast tissue, as an adjunct to mammography and ultrasound. Tc-99m sestamibi accumulates in metabolically active tumor cells due to their high mitochondrial density and preserved membrane potentials.
• Tumor imaging (selected indications): In certain clinical contexts, Tc-99m sestamibi may be used to evaluate multidrug resistance in tumors, characterize thyroid nodules, image pediatric brain tumors, or localize other sestamibi-avid neoplasms.

The choice of indication, imaging protocol, and dose must always be made by a qualified nuclear medicine physician or authorized prescriber in accordance with international guidelines, including those published by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the American Society of Nuclear Cardiology (ASNC), and the International Commission on Radiological Protection (ICRP). Self-administration is not possible, and Stamicis is only handled within authorized nuclear medicine facilities.

What Should You Know Before Using Stamicis?

Quick Answer: Stamicis must not be used in patients with known hypersensitivity to sestamibi or its excipients. Pregnancy must be excluded in women of childbearing potential, and breastfeeding should be interrupted for at least 24 hours after administration. Use in children requires weight-based dose adjustment. Patients should inform their doctor about all medications, especially those that affect cardiac stress testing (beta-blockers, nitrates, caffeine).

Contraindications

Stamicis (as Tc-99m sestamibi injection after radiolabeling) must not be used in the following situations:

• Hypersensitivity: Known hypersensitivity to sestamibi, to any of the excipients in the kit, or to technetium-99m is an absolute contraindication. Patients who have previously experienced severe allergic or anaphylactic reactions to any sestamibi product should not receive Stamicis.
• Pregnancy: Unless imaging is deemed essential and the potential benefit clearly outweighs the fetal radiation risk, radiopharmaceuticals should be avoided during pregnancy. Stamicis is generally contraindicated in confirmed pregnancy; exposure of the fetus to ionizing radiation must be justified on a case-by-case basis by a specialist.
• Inappropriate clinical setting: Stamicis must not be handled or administered outside appropriately licensed and equipped nuclear medicine facilities. Administration to patients in whom a scientifically justified diagnostic question cannot be answered by the procedure is not appropriate.

In the context of pharmacologic myocardial stress (e.g., with adenosine, regadenoson, or dipyridamole), additional contraindications apply to the stress agent itself (such as severe asthma or reactive airway disease for adenosine), and these must be reviewed separately by the prescribing cardiologist or nuclear medicine specialist.

Warnings and Precautions

Administration of Tc-99m sestamibi requires adherence to radiation safety standards and clinical precautions. Before and during the procedure, the nuclear medicine team should consider the following:

• Radiopharmacy handling: Stamicis must only be prepared, handled, and administered by qualified personnel in facilities authorized to handle radioactive materials, in accordance with local regulations (e.g., EU Basic Safety Standards Directive, IAEA standards, national radiation protection agencies). Quality control testing of the reconstituted solution (radiochemical purity >90%) is mandatory before administration.
• Cardiac stress testing precautions: For pharmacologic stress with vasodilators (adenosine, regadenoson, dipyridamole), patients should avoid caffeine and methylxanthines (including coffee, tea, cola, chocolate, and some medications such as aminophylline and theophylline) for 12-24 hours before the test, as these substances antagonize adenosine receptors and blunt the stress response. Emergency equipment and reversal agents (e.g., aminophylline for adenosine-related side effects) must be immediately available.
• Concurrent cardiac medications: Beta-blockers, calcium channel blockers, and nitrates may attenuate exercise-induced ischemia and reduce the sensitivity of myocardial perfusion imaging for the detection of coronary artery disease. The referring physician should weigh the risk of medication withdrawal against the diagnostic need. In patients with known coronary disease being assessed for risk stratification on current therapy, medications are typically continued.
• Image quality considerations: Subdiaphragmatic (gastrointestinal, hepatic, and gallbladder) uptake of Tc-99m sestamibi may interfere with interpretation of inferior myocardial walls. A light fatty meal or a glass of milk/water between injection and imaging is commonly recommended to hasten hepatobiliary clearance and improve image quality.
• Pre-existing cardiac disease: In patients with unstable angina, recent myocardial infarction, decompensated heart failure, severe aortic stenosis, uncontrolled arrhythmias, or severe hypertension, exercise or pharmacologic stress imaging should only be undertaken with appropriate risk assessment and monitoring, ideally by a cardiologist experienced in stress testing.
• Renal and hepatic impairment: Tc-99m sestamibi is cleared by both hepatobiliary and renal routes; dose reduction is generally not required in renal or hepatic impairment, but altered biodistribution may affect image quality and interpretation in severe dysfunction.
• Pediatric use: Activity must be adjusted for body weight according to the EANM Paediatric Dosage Card or equivalent national recommendations. Children are more sensitive to the stochastic effects of ionizing radiation, so special justification and dose optimization are mandatory.
• Post-procedure precautions: Patients should be encouraged to drink fluids and void frequently after injection to reduce bladder wall and urinary tract radiation exposure. Residual radioactivity is minimal after 24-48 hours and generally does not require additional precautions, though close contact with pregnant women and young children may reasonably be limited for a few hours.

Pregnancy and Breastfeeding

Before administration of Tc-99m sestamibi to a woman of childbearing potential, the nuclear medicine service should confirm the absence of pregnancy. If the menstrual period has been missed, pregnancy must be assumed until proven otherwise, and imaging should be postponed unless the clinical situation is urgent. When an alternative imaging technique without ionizing radiation (such as echocardiography, cardiac magnetic resonance imaging, or ultrasound) is equally suitable, it should generally be preferred for pregnant patients.

Tc-99m sestamibi crosses the placenta in small amounts, and the fetal absorbed dose from a typical adult dose of 1,000 MBq is estimated at approximately 5-8 milligray (mGy) to the gestational sac in early pregnancy, which is below the threshold for deterministic effects but carries a very small stochastic risk. If imaging is essential during pregnancy, the lowest activity consistent with image quality should be used and the decision carefully documented by a nuclear medicine specialist.

For breastfeeding women, Tc-99m sestamibi is excreted into breast milk in limited quantities. Current international guidance (EANM, ICRP) recommends that breastfeeding be interrupted for at least 24 hours after administration, with milk expressed during this period being discarded. Close physical contact with infants and young children should also be limited during the first 24 hours after injection to reduce their external exposure to the residual radiation from the mother.

How Does Stamicis Interact with Other Drugs?

Quick Answer: Tc-99m sestamibi itself has very few direct pharmacological interactions, but several medications and substances affect the accuracy of myocardial perfusion imaging. Caffeine and methylxanthines block adenosine-based stress tests, beta-blockers and nitrates reduce sensitivity of exercise stress, and amiodarone can influence parathyroid imaging. Always inform your nuclear medicine team about all prescription drugs, over-the-counter medicines, and dietary substances.

Because Tc-99m sestamibi is administered in extremely small (tracer) quantities, it exerts no direct pharmacological effect on the body and has no classical pharmacokinetic interactions comparable to those of therapeutic drugs. However, several categories of medications interact with the diagnostic accuracy of Stamicis by either altering the physiological stimulus used to provoke ischemia or by influencing the biodistribution of the tracer. These interactions must be anticipated, documented, and communicated between the referring clinician, the imaging specialist, and the patient.

Major Interactions

The clinically most important interactions with Stamicis concern caffeine and other methylxanthines when pharmacologic vasodilator stress is planned. Adenosine, regadenoson, and dipyridamole all act by increasing extracellular adenosine levels, which bind to adenosine A2A receptors on coronary smooth muscle and induce vasodilation. Caffeine is a potent competitive antagonist at these same receptors and can, even in modest doses (such as a single cup of coffee), substantially blunt or abolish the vasodilator response. This produces a false-negative perfusion study and leads to missed ischemia. International guidelines (SNMMI, ASNC, EANM) uniformly recommend abstinence from all caffeine-containing beverages, foods, and medications for at least 12-24 hours before the test. Some centers require 24 hours as a strict cut-off.

Pharmacologic theophylline products used for chronic obstructive pulmonary disease or asthma are equally problematic for adenosine-based stress. Where clinically safe, these are withheld for 24-48 hours, or an alternative stress modality (such as exercise or dobutamine stress) is chosen.

Beta-blockers and calcium channel blockers can reduce the sensitivity of exercise myocardial perfusion imaging for the detection of obstructive coronary disease by limiting heart rate and blood pressure response. Whether to withhold these medications depends on the clinical question: for diagnostic studies in a symptomatic patient without known coronary disease, a 24-48 hour washout is often appropriate; for risk stratification in a patient on optimal medical therapy, medications are generally continued so that the study reflects "on-treatment" physiology.

Minor Interactions

Thyroid-affecting medications (levothyroxine, methimazole, carbimazole, propylthiouracil) and recent iodinated contrast exposure can alter thyroid sestamibi uptake patterns, which is particularly relevant for dual-phase parathyroid scintigraphy. When possible, the nuclear medicine team should be informed of these medications and iodinated contrast studies in the preceding weeks, and adjunctive imaging (high-resolution ultrasound, 4D-CT, or [18F]fluorocholine PET/CT) may be considered when scintigraphy alone is inconclusive.

In tumor imaging, overexpression of the multidrug resistance protein P-glycoprotein (P-gp / MDR1) actively effluxes sestamibi from cancer cells, reducing tumor uptake. This can be exploited to assess chemotherapy resistance, and interactions with chemotherapeutic agents and P-gp modulators should be documented in tumor-imaging studies.

Because Stamicis is administered as a tracer in nanomolar quantities, it does not alter the pharmacokinetics of concomitant medications and there is no need to adjust the dose of any other drug on the basis of the procedure.

What Is the Correct Dosage of Stamicis?

Quick Answer: Stamicis dosing is expressed as activity of Tc-99m sestamibi (MBq or mCi), not mass. For adults, typical activities are 250-500 MBq for rest or stress myocardial perfusion imaging (6.7-13.5 mCi), with dual-injection (same-day or two-day) protocols. Pediatric dosing follows the EANM Paediatric Dosage Card based on body weight. The final activity, protocol, and imaging time are determined by a nuclear medicine physician.

The dose of Stamicis is expressed as radioactivity in megabecquerels (MBq) or millicuries (mCi) of Tc-99m sestamibi, rather than in milligrams of the sestamibi molecule, because the amount of administered sestamibi is pharmacologically negligible. Dosing is individualized based on the indication, the imaging protocol (single-day or two-day), the patient's body weight, the equipment used (gamma camera sensitivity), and national diagnostic reference levels. All dosing decisions should be made by a qualified nuclear medicine physician in line with international and local guidelines.

Adults – Myocardial Perfusion Imaging

Adults – Parathyroid Scintigraphy

Adults – Scintimammography (Breast Imaging)

Children (Paediatric Dosing)

Elderly Patients

No specific dose adjustment is required for older patients based solely on age. Individualized activity is based on body weight and imaging protocol. Care is required in frail patients undergoing exercise or pharmacologic stress, where pre-procedure risk assessment and monitoring by a cardiologist or experienced nuclear medicine physician is essential. Renal and hepatic function should be considered in the context of concomitant medications rather than for activity adjustment of the tracer itself.

Missed Dose

Because Stamicis is administered only in a controlled clinical setting under the direct supervision of a nuclear medicine team, the concept of a "missed dose" does not apply in the usual sense. If an appointment is missed, the study is rescheduled. Unused, radiolabeled product that cannot be administered within its shelf life is disposed of as radioactive waste according to the facility's radiation safety procedures. Patients do not self-administer Stamicis at home.

Overdose

Because the pharmacological mass of sestamibi administered is extremely small, a chemical or pharmacological overdose of Stamicis is not a realistic clinical concern. The primary risk in the event of administration of a higher-than-intended activity of Tc-99m sestamibi is an increased radiation dose to the patient. Management strategies include encouraging fluid intake and frequent voiding (to accelerate renal clearance), promoting defecation and hepatobiliary flow to reduce intestinal transit time, and recording the incident in the patient's dosimetric history. In the very rare event of a known large overactivity exposure, a medical physicist should be consulted for individualized dosimetry assessment and, if necessary, radioprotection advice.

What Are the Side Effects of Stamicis?

Quick Answer: Adverse reactions to Stamicis (Tc-99m sestamibi) are uncommon and usually mild. The most frequently reported effect is a transient metallic or bitter taste immediately after injection. Headache, flushing, and injection site reactions are occasional. Serious hypersensitivity reactions are rare. The small additional stochastic radiation risk is inherent to any nuclear medicine procedure. Contact the imaging team if you experience severe itching, swelling, difficulty breathing, or chest pain after the injection.

Tc-99m sestamibi has been used clinically for more than three decades, with millions of doses administered worldwide. Post-marketing surveillance and clinical trials have established it as a well-tolerated diagnostic agent with a favorable safety profile. Because the administered mass of sestamibi is negligible (micrograms rather than milligrams or grams), classical dose-dependent adverse drug reactions are rare. Most reported side effects reflect either the route of administration, a transient sensory effect (taste), or, less commonly, immunologic hypersensitivity.

The side effect profile may interact with the context of the procedure. Many "side effects" reported during a myocardial perfusion study (chest pain, dyspnea, dizziness, palpitations, transient ECG changes) relate to the stress test itself (exercise or pharmacologic vasodilator) rather than to sestamibi. These are carefully distinguished by the imaging team.

Radiation-Related Risk

In addition to the rare acute adverse drug reactions listed above, all nuclear medicine procedures entail a small stochastic radiation risk (primarily the small, long-term increased risk of cancer induction). For a typical adult myocardial perfusion study with Tc-99m sestamibi, the effective dose is approximately 7-12 mSv, which is comparable to about 2-3 years of natural background radiation. The International Commission on Radiological Protection (ICRP) and national authorities consider this risk acceptable when weighed against the diagnostic and prognostic benefit in appropriately selected patients. Dose optimization (ALARA – As Low As Reasonably Achievable), justification, and use of modern camera systems are the principal strategies to minimize this risk.

Most side effects of Stamicis are mild and self-limited. Pre-procedure counseling, good hydration after the study, and avoidance of the interacting substances listed in the previous section all help to minimize the likelihood of side effects and ensure an optimal diagnostic result.

How Should Stamicis Be Stored?

Quick Answer: Stamicis is stored exclusively within licensed hospital or commercial radiopharmacy facilities. The unreconstituted kit is stored at room temperature (below 25°C), protected from light, in its original carton. Once radiolabeled with Tc-99m pertechnetate, the resulting solution is stored in a shielded container and must be used within the labeled expiry period (typically up to 10 hours after reconstitution) and in accordance with radiation protection regulations.

Correct storage of Stamicis is critical both to maintain the chemical stability of the sestamibi precursor and to comply with strict national and international radiation safety regulations. Unlike conventional medicines, Stamicis and its radiolabeled product are handled only in licensed facilities with purpose-built radiopharmacy infrastructure, and patients never take Stamicis home or store it themselves.

• Unreconstituted (non-radioactive) kit: The lyophilized vials are stored at below 25°C (or refrigerated 2-8°C where specified by the Summary of Product Characteristics), protected from light, in their original outer carton. Kits must not be used after the printed expiry date.
• Radiolabeled Tc-99m sestamibi solution: After reconstitution with sodium pertechnetate and the brief heating step, the radiolabeled solution is stored in a lead-shielded container within a temperature-controlled radiopharmacy hot-lab. The shelf life of the reconstituted product is typically up to 10 hours at room temperature, as specified in the SmPC, but individual product labels must always be followed.
• Shielding and access control: Vials and syringes are placed in lead containers sized for the emitted 140 keV gamma photons of Tc-99m. Access to the radiopharmacy is restricted to trained, authorized personnel. All movements of radioactive materials are logged.
• Quality control: Before release for patient administration, each batch is tested for radiochemical purity (typically by thin-layer chromatography); radiochemical purity must be ≥90%. Appearance, pH, and absence of particles are also verified.
• Transport: If Tc-99m sestamibi is transported from a central radiopharmacy to satellite clinics, it is shipped in approved Type A radiation transport packaging, clearly labeled, and accompanied by the relevant shipping documentation in compliance with IAEA and national transport regulations.
• Waste disposal: Unused radiolabeled product, vials, syringes, absorbent paper, and personal protective equipment contaminated with radioactive material are stored in dedicated decay-storage areas until radioactivity falls below regulatory exemption limits (typically 10 half-lives, or about 60 hours for Tc-99m), then disposed of as ordinary clinical waste, or handled according to institutional procedures for radioactive waste.
• Visual inspection: Before use, the reconstituted solution should be visually inspected in the radiopharmacy. It should be clear and colorless to slightly yellow. Solutions that are discolored, cloudy, or contain visible particles must not be used.
• Do not freeze the unreconstituted kit unless specified in the SmPC: Freezing and repeated thawing can denature the lyophilized powder and compromise radiolabeling yield.

Patients should never be given Stamicis vials to store or transport themselves. All aspects of storage, handling, and disposal are the responsibility of the licensed nuclear medicine facility and its qualified radiopharmacy staff.

What Does Stamicis Contain?

Quick Answer: Each vial of Stamicis contains 1.0 mg of tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate as the active substance. Inactive ingredients typically include stannous chloride dihydrate (as reducing agent), cysteine hydrochloride, sodium citrate, and mannitol. The product contains no radioactivity until it is combined with sodium pertechnetate [99mTc] at the radiopharmacy.

Active Ingredient

The active substance in Stamicis is tetrakis(2-methoxyisobutylisonitrile)copper(I) tetrafluoroborate, a coordination complex of copper(I) with four isonitrile ligands. Each vial contains 1.0 mg of this complex. Upon reconstitution with sodium pertechnetate (99mTc) in the presence of a stannous reducing agent, the copper is replaced by Tc-99m to form the final radiopharmaceutical, [99mTc]-sestamibi (International Non-proprietary Name: technetium (99mTc) sestamibi; chemical abbreviation: MIBI; systematic name: hexakis(2-methoxyisobutylisonitrile)-technetium(I)).

The resulting Tc-99m sestamibi complex is a lipophilic, monocationic compound that readily crosses cell membranes by passive diffusion and accumulates within mitochondria in proportion to regional blood flow and mitochondrial membrane potential. It is this biodistribution that underlies its diagnostic utility in cardiac, parathyroid, and tumor imaging.

Inactive Ingredients (Excipients)

In addition to the active copper(I) complex, Stamicis kits typically contain the following excipients (precise composition may vary by regional product license; the Summary of Product Characteristics is the authoritative source):

• Stannous chloride dihydrate (SnCl₂·2H₂O): A reducing agent essential for the radiolabeling reaction. It reduces pertechnetate (Tc[VII]O₄⁻) to a lower oxidation state (Tc[I] in the final sestamibi complex) so that it can be incorporated into the sestamibi ligand system.
• Cysteine hydrochloride monohydrate: A chemical stabilizer that protects the labile reduced tin and contributes to the stability and radiochemical purity of the final product.
• Sodium citrate dihydrate: A buffering and chelating agent that contributes to maintaining the correct pH for the reconstituted injection.
• Mannitol: A bulking agent that gives the lyophilized cake its structure and facilitates rapid and complete reconstitution when sodium pertechnetate solution is added.

The final radiopharmaceutical, after radiolabeling, also contains the radionuclide technetium-99m, produced by the decay of molybdenum-99 in a technetium generator, and the accompanying residual elements from the pertechnetate eluate. The injectable solution's pH is typically in the range of 5.5 to 5.9 and is compatible with intravenous administration.

Frequently Asked Questions About Stamicis